Idera Pharmaceuticals, Inc.
167 Sidney Street
About Idera Pharmaceuticals, Inc.Idera Pharma develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.
For more information, visit www.iderapharma.com.
365 articles with Idera Pharmaceuticals, Inc.
6/4/2018There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
Idera Pharmaceuticals Increases Operational Efficiency of Global Oncology Program with Medidata Clinical Cloud
Medidata’s Solutions to Accelerate Studies, Improve Data Quality, and Drive Greater Patient Enrollment
BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals
BioCryst Mails Letter to Stockholders Highlighting Compelling Upside Opportunity
The combined company will be renamed upon closing and will be led by Vincent Milano, CEO of Idera, who will also serve as a member of the Board.
Company to present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:00 AM PT/2:00 PM ET.
Why investors may want to keep an eye on Idera Pharmaceuticals and Ekso Bionics.
U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma
FDA’s Fast Track program is designed to expedite the development and review of drugs and biologics to treat serious or life-threatening conditions.
Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)
These data will be presented at 4:45 P.M. E.T. on Saturday, November 11th.
Net loss applicable to common stockholders for the three months ended September 30, 2017 was $14.5 million, or $0.10 per basic and diluted share, compared to a net loss applicable to common stockholders of $12.9 million.
The Company has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock
Youssef El Zein, Managing Partner of Pillar Invest Corporation has elected to step down from the company’s Board of Directors, effective immediately.
The company intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering. In connection with this offering.
Idera Pharma Presents Positive Phase I Data For Intratumoral IMO-2125 In Combination With Ipilimumab Demonstrating An Overall Response Rate (ORR) Of 44% In Melanoma Patients Refractory To Anti-PD1 Therapy
Idera Pharma Presents Pre-Clinical Data From IMO-2125 Treatment In Combination With Ipilimumab That Demonstrates Induction Of Durable Anti-Tumor Responses Associated With Tumor-Specific Memory
Idera Pharma Advances Investigational Treatment—Intratumoral IMO-2125 In Combination With Ipilimumab - For Unmet Need In Anti-PD-1 Refractory Metastatic Melanoma